{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:35:28Z","timestamp":1771648528502,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pompe disease is a lysosomal storage disorder defined by a mutation in the GAA gene encoding alpha-1,4-glucosidase alpha (acid maltase). Pompe disease encompasses a range of clinical presentations that are broadly characterized as either classic infantile Pompe disease or late-onset Pompe disease (LOPD). LOPD is a milder manifestation of the disease that presents after the first year of life and is typically characterized by mild proximal muscle weakness and lack of cardiac involvement compared to the classic infantile form. The mainstay of treatment is enzyme replacement therapy (EnRT). Decreased bone mineral density (BMD) is frequently encountered in LOPD. While bone loss is thought to be due to mechanical unloading secondary to the progressive muscle weakness associated with the disease, there is a lack of tissue-level data in support of this mechanism. We describe a 60-yr-old female with LOPD managed with EnRT who presented with proximal muscle weakness and decreased BMD on dual-energy X-ray absorptiometry. Undecalcified bone histology showed low turnover osteoporosis, and treatment was initiated with romosozumab. Romosozumab specifically may provide a promising osteoporosis therapy for LOPD-associated osteoporosis. As a sclerostin inhibitor, it both inhibits bone resorption and promotes new bone formation. We additionally emphasize that bone biopsy should be considered as a useful diagnostic tool in the evaluation of osteoporosis associated with uncommon pathologies, since bone histology provides more specific tissue-level information over clinical and laboratory evaluation as well as substantive guidance for treatment.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf045","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T10:28:46Z","timestamp":1743676126000},"source":"Crossref","is-referenced-by-count":1,"title":["Bone disease and osteoporosis associated with Pompe disease"],"prefix":"10.1093","volume":"9","author":[{"given":"Lucas","family":"Maxey","sequence":"first","affiliation":[{"name":"University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Freibert","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auremil","family":"Quinonez","sequence":"additional","affiliation":[{"name":"Bone Diagnostic and Research Laboratory, Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Malluche","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-521X","authenticated-orcid":false,"given":"Madhumathi","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky College of Medicine , Lexington, KY 40536 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"1","key":"2025041314124692700_ref1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12883-015-0412-3","article-title":"Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group","volume":"15","author":"Al Jasmi","year":"2015","journal-title":"BMC Neurol"},{"issue":"1","key":"2025041314124692700_ref2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijns6010009","article-title":"The first year experience of newborn screening for Pompe disease in California","volume":"6","author":"Tang","year":"2020","journal-title":"Int J Neonatal Screen"},{"issue":"5","key":"2025041314124692700_ref3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline [published correction appears in Genet Med. 2006 Jun;8(6):382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E]]","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"issue":"2","key":"2025041314124692700_ref4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","article-title":"Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease","volume":"11","author":"Lim","year":"2015","journal-title":"Autophagy"},{"issue":"5","key":"2025041314124692700_ref5","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jbiomech.2004.05.040","article-title":"Effects of non-contractile inclusions on mechanical performance of skeletal muscle","volume":"38","author":"Drost","year":"2005","journal-title":"J Biomech"},{"issue":"3","key":"2025041314124692700_ref6","doi-asserted-by":"publisher","first-page":"107644","DOI":"10.1016\/j.ymgme.2023.107644","article-title":"Effects of enzyme replacement therapy on bone density in late onset Pompe disease","volume":"140","author":"Avanti","year":"2023","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2025041314124692700_ref7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"12","key":"2025041314124692700_ref8","doi-asserted-by":"publisher","first-page":"CD012993","DOI":"10.1002\/14651858.CD012993.pub2","article-title":"Enzyme replacement therapy for late-onset Pompe disease","volume":"12","author":"Dalmia","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"2025041314124692700_ref9","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.3390\/jcm10214828","article-title":"A systematic review and meta-analysis of enzyme replacement therapy in late-onset Pompe disease","volume":"10","author":"Dornelles","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"2025041314124692700_ref10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.5812\/ijem.4967","article-title":"Bone density in patients with late onset Pompe disease","volume":"10","author":"Papadimas","year":"2012","journal-title":"Int J Endocrinol Metab"},{"issue":"3","key":"2025041314124692700_ref11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.bone.2010.06.021","article-title":"Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density","volume":"47","author":"van den Berg","year":"2010","journal-title":"Bone"},{"issue":"1","key":"2025041314124692700_ref12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s13104-017-2681-y","article-title":"Improvement of bone mineral density after enzyme replacement therapy in Chinese late-onset Pompe disease patients","volume":"10","author":"Sheng","year":"2017","journal-title":"BMC Res Notes"},{"key":"2025041314124692700_ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jot.2015.08.004","article-title":"Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: a general review","volume":"4","author":"Suen","year":"2016","journal-title":"J Orthop Translat"},{"key":"2025041314124692700_ref14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bone.2016.10.008","article-title":"Sclerostin's role in bone's adaptive response to mechanical loading","volume":"96","author":"Galea","year":"2017","journal-title":"Bone"},{"key":"2025041314124692700_ref15","doi-asserted-by":"publisher","first-page":"1364694","DOI":"10.3389\/fphys.2024.1364694","article-title":"Osteocyte-mediated mechanical response controls osteoblast differentiation and function","volume":"15","author":"Buck","year":"2024","journal-title":"Front Physiol"},{"key":"2025041314124692700_ref16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/B978-0-12-415853-5.00008-X","volume-title":"Osteoporosis","author":"Arnett","year":"2013","edition":"4th"},{"issue":"4","key":"2025041314124692700_ref17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.cmet.2007.09.007","article-title":"Estrogen and bone: osteoclasts take center stage","volume":"6","author":"Novack","year":"2007","journal-title":"Cell Metab"},{"issue":"11","key":"2025041314124692700_ref18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2025041314124692700_ref19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ymgme.2010.09.002","article-title":"Body composition analysis in late-onset Pompe disease","volume":"102","author":"Papadimas","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"7","key":"2025041314124692700_ref20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/00207454.2020.1835902","article-title":"Body composition and 6 minute walking ability in late-onset Pompe disease patients after 9 years of enzyme replacement therapy","volume":"132","author":"Terzis","year":"2022","journal-title":"Int J Neurosci"},{"issue":"4","key":"2025041314124692700_ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040787","article-title":"Osteoporosis treatment with anti-sclerostin antibodies-mechanisms of action and clinical application","volume":"10","author":"Rauner","year":"2021","journal-title":"J Clin Med"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf045\/62852199\/ziaf045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/5\/ziaf045\/62852199\/ziaf045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/5\/ziaf045\/62852199\/ziaf045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T14:12:56Z","timestamp":1744553576000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf045\/8104832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf045","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,30]]},"article-number":"ziaf045"}}